we are so right Stanley15 Apr 2023 11:28
hVIVO – a company which focuses on testing infectious and respiratory disease products using human challenge clinical trials – has announced positive data from a first-in-human phase 1 clinical study evaluating the safety and immunogenicity of AGS-v PLUS.
AGS-v PLUS is a vaccine candidate against arboviral diseases that target the saliva of the mosquito rather than its pathogens. The therapy is owned by Imutex – a joint venture with PepTcell – in which hVIVO has a 49% shareholding